Advertisement

The Pharmacology and Clinical Pharmacology of Defibrotide: A New Profibrinolytic, Antithrombotic and Anti-Platelet Substance

  • O. N. Ulutin
  • S. Balkuv-Ulutin
  • M. S. Ugur
  • T. Ulutin
  • Y. Özsoy
  • G. Çizmeci
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 281)

Abstract

Defibrotide, a deoxypolyribonuclide, has been found to modulate endothelial cell function causing increase in t-PA and decrease in PAI levels and also increase in PGI2 production. In addition, it increases platelet c-AMP levels and decreases MDA and TXB2 formation in human. Defibrotide inhibits platelet aggregate formation in vitro experiments as well as end-to-end anostomosis in rats. So, defibrotide inhibits the activation of platelets. Besides an increase of protein C and S levels a synergic action of heparin was observed in animal experiments. A strong antithrombotic effect has been observed in animal models.

The drug has a beneficial effect in the cases of DVT, POVD, stroke and thromboembolism. Through its action we may say that the drug acts in a novel fashion in contrast to the other drugs used in this area.

Defibrotide is a single-stranded polydeoxyribonucleotide obtained from deoxyribonucleic acid of mammalian lungs by controlled depolimerization. Since 1981 in our laboratory and in the clinical department we have been investigating a newly developed agent defibrotide in vitro experiments, animal experiments, and also its clinical pharmacology and clinical application.

Some of our findings are already published and compared with literature (40, 43, 46). Because of the limited space we are not going to review the literature in detail but we are going to summarize our observations on this compound in the following order. I — in vitro experiments, II — Animal experiments, III — clinical pharmacology in human.

Keywords

Clinical Pharmacology Antithrombotic Effect Antithrombotic Activity Thrombosis Research Anti Thrombotic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. Bilsel, Y. Taga, A. S. Yalgin, K. Emerk, and O. N. Ulutin, Effect of defibrotide and endothelial cell growth supplement on human endothelial cells in culture. Haematology Reviews, 3:29–34 (1989).Google Scholar
  2. 2.
    S. Balkuv-Ulutin (unpublished observation 1985).Google Scholar
  3. 3.
    S. Balkuv-Ulutin, E. Goldenberg, M. Bali, A. Kavukçu, and O. N. Ulutin, Clinical Results with Defibrotide in Patients with Acute Stroke. Haemostasis, 18: Suppl. 2, 81 (1988).Google Scholar
  4. 4.
    S. Balkuv-Ulutin, M. Hacihanefioglu, and O. N. Ulutin, Clinical and laboratory results obtained with defibrotide in the cases of acute stroke (Abst. 1874). XIIth Congress of ISTH, Aug. 19–25, (1989) Tokyo.Google Scholar
  5. 5.
    S. Balkuv-Ulutin, T. Ulutin, G. Kaya, T. Yardimci, and O. N. Ulutin, The effect of defibrotide on protein C levels in human (preliminary results). Thrombosis and Hemorrhagic Diseases, ed. by O.N. Ulutin and H. Vinazzer, Gözlem Printing and Publishing Co., Istanbul (1986) pp. 409–410.Google Scholar
  6. 6.
    S. Balkuv-Ulutin, T. Ulutin, Y. Özsoy, G. Çizmeci, T. Yardimci, B. Ferhanoglu, and O. N. Ulutin, The effect of defibrotide on t-PA and PAI levels and also platelet function. Marmara Med. J., 1:48 (1988).Google Scholar
  7. 7.
    S. Balkuv-Ulutin, T. Ulutin, Y. Özsoy, B. Ferhanoglu, and O. N. Ulutin, The effects of defibrotide on tissue plasminogen activator and molecular markers of platelets (Abs. 316). Xth Internat. Congress on Thrombosis, May 23–27, 1988 Athens.Google Scholar
  8. 8.
    A. Çevikbas, O. Ulutin, U. Çevikbas, T. Yardimci, and T. Erbengi, Defibrotidin fare karacigerine etkisi. (An ultrastructural study). Proc. of IXth National Congress of Electronmicroscopy, May 29–31, (1989) p. 255–256.Google Scholar
  9. 9.
    G. Çizmeci: In vivo effect of defibrotide on platelet c-AMP and blood prostanoid levels. Haemostasis, 16: Suppl. 1, 31–35, (1986).PubMedGoogle Scholar
  10. 10.
    G. Cizmeci, and O. N. Ulutin: In vitro effect of defibrotide on the production of PGI2 and TXB2 in leucocytes (Abs. 1464). Thrombosis and Haemostasis, 54:210 (1985).Google Scholar
  11. 11.
    G. Çizmeci, and O. N. Ulutin: Prostanoid synthesis in isolated leucocytes and in-vitro effect of defibrotide. Thrombosis and Hemorrhagic Disease,ed. by O.N. Ulutin and H. Vinazzer, Gözlem Printing and Publishing Co., Istanbul (1986) pp. 199–204.Google Scholar
  12. 12.
    G. Çizmeci, and O. N. Ulutin: Defibrotide antithrombotic effect existing from modified endothelium function (Abst. 824). XXth Congress ISH, Sept. 1–7, (1984) Buenos Aires.Google Scholar
  13. 13.
    G. Çizmeci, and O. N. Ulutin: Corrective effect of defibrotide on altered endothelium cell function in atherosclerosis (Abst. 515). Thromb. Haemost., 54:87 (1985).Google Scholar
  14. 14.
    S. Coccheri, V. de Rosa, A. G. Dettori, D. Ponari, B. Bizzi, N. Ciaverella, and A. Isidori: Effect of fibrinolysis of a new antithrombotic agent: Fraction P (defibrotide) Int. J. Clin. Pharmacol. Res.,11:227–245 (1982).Google Scholar
  15. 15.
    U. Cornelli, and M. Nazzari: Defibrotide: An overview of clinical pharmacology and early clinical studies. Seminars in Thrombosis and Hemostasis, 14:64–70 (1988).PubMedGoogle Scholar
  16. 16.
    T. Di Perri, F. Laghi-Pasini, P. L. Capecchi, L. Ceccatelli, A. L. Pasqui, and A. Orrico: Defibrotide in vitro inhibits neutrophil activation by a Ca** involving mechanism. Int. J. Tiss. Reac., IX (5): 399–406 (1987).Google Scholar
  17. 17.
    T. Di Perri, and F. L. Pasini: Effect of defibrotide on polymorphonuclear leukocytes: Modulation of calcium entry and availability. Seminars in Thrombosis and Haemostasis, 14:Suppl. 23–26 (1988).Google Scholar
  18. 18.
    T. Di Perri, A. Vittoria, G. L. Messa, and R. Cappelli, Defibrotide therapy for thrombophlebitis: Controlled clinical trial. Haemostasis, 16: Suppl. 1, 42–47 (1986).PubMedGoogle Scholar
  19. 19.
    D. S. Fair, R. A. Marlar, and E. G. Levin, Human endothelial cells synthetize protein S. Blood, 67:1168–1171 (1986).PubMedGoogle Scholar
  20. 20.
    J. Fareed, J. M. Walenga, D. A. Hoppenstead, A. Kumar, O. N. Ulutin, U. Cornelli, Pharmacologic profiling of defibrotide in experimental models. Seminars in Thrombosis and Haemostasis, 14: Suppl. 1, 27–37 (1988).Google Scholar
  21. 21.
    G. Fumagalli, E. Angelaccio, N. Lambardo, and Francisco Clementi, Morphometric and ultrastructural study of experimental venous thrombosis. Haemostasis, 17:361–370 (1987).PubMedGoogle Scholar
  22. 22.
    S. Ilhan-Berkel, S. Balkuv-Ulutin, and O. N. Ulutin, Fibrinolytic effect in man of a new extractive drug: defibrotide. VIIth Internat. Congr. on Fibrinolysis, Venice (1984) Haemostasis, 14: Suppl. (1984).Google Scholar
  23. 23.
    N. Ilhan-Berkel, S. Balkuv-Ulutin, and O. N. Ulutin, The effect of defibrotide on the venous stasis test (Cuff test). VIIIth Internat. Congr. on Thrombosis, June 4–7, (1984) (Abst. 110).Google Scholar
  24. 24.
    A. Kumar, J. Fareed, W. H. Wehrmacher, D. Hoppensteadt, O. N. Ulutin, and J. M. Walenga, Endothelial function modulation and control of vascular or thrombotic disorders: Experimental results with a polydeoxyribonucleotide agent defibrotide. Blood, 68:Suppl. 1, 356c (1986).Google Scholar
  25. 25.
    A. Kumar, J. Fareed, W. H. Wehrmacher, D. Hoppensteadt, O. Ulutin, and J. M. Walenga, Endothelial function modulation and control of vascular or thrombotic disorders: Experimental results with a polydeoxyribonucleotide agent defibrotide. Thrombosis and Haemostasis, 58:350 (1987).Google Scholar
  26. 26.
    P. Löbel, and K. Schrör: Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart. Naunyn Schmiedeberg s Arch. Pharmacol., 331:125–130 (1985).CrossRefGoogle Scholar
  27. 27.
    E. M. Pogliani, M. Salvatore, C. Fausti, R. Girardello, and C. Marelli, Effects of a defibrotide-heparin combinations on some measures of haemostasis in healthy volunteers J. Internat. Med. Res.,17:36–40 (1989).Google Scholar
  28. 28.
    E. M. Pogliani, M. Salvatore, C. Faust, C. Marelli, Studio di bioequivalenza di due schemi posologici di defibrotide su parametri della fibrinolizi in soggetti valontari sani Farmaci and Terapi,4:1–5 (1987).Google Scholar
  29. 29.
    R. Porta, R. Pescador, M. Martovani, P. Alberico, R. Tettamanti, and G. Prino, Interference of defibrotide with heparin’s anticoagulant activity and pharmacokinetics 6th Meeting of the Danubian League Against Thrombosis and Hemorrhagic Disorders,May 31-June, 3: (1989) p.46.Google Scholar
  30. 30.
    G. Prino, M. Mantovani, and R. Niada, Antithrombotic activity of a polydexynucleotidic-like substance (Fraction P). Advance in coagulation fibrinolysis, platelet aggregation and atherosclerosis,ed. by A. Stano C.E.P.I., Roma (1978), pp. 288–289.Google Scholar
  31. 31.
    R. Niada, M. Mantovani, G. Prino, R. Pescador, F. Berti, C. Onini, and G. C. Folco, Antithrombotic activity of a polydeoxyribanucleatidic substance extracted from mammalian organs. A possible link with prostacyclin. Thrombosis Research, 23:233–246, (1981).PubMedCrossRefGoogle Scholar
  32. 32.
    R. Niada, M. Mantovani, G. Prino, R. Pescador, R. Porta, F. Berti, G. C. Folco, C. Onini, and T. Vigano, PGI2-generation and antithrombotic activity of orally administered defibrotide. Pharmacol. Res. Commun.,14:949–957 (1982).PubMedCrossRefGoogle Scholar
  33. 33.
    R. Niada, R. Pescador, R. Porta, M. Mantovani, and G. Prino, Defibrotide is anti-thrombotic and thrombolytic against rabbit venous thrombosis. Haemostasis,16: Suppl. 3–8 (1986).PubMedGoogle Scholar
  34. 34.
    A. F. Ozer, M. N. Pamir, T. Erbengi, and O. N. Ulutin, The early and late effect of defibrotide on the platelet aggregation and reendothelization on the microarteria suture-line. XVth World Congr. of Internat. Union of Angiology. Sept. 17–22, (1989) Rome.Google Scholar
  35. 35.
    A. F. Ozer, M. N. Pamir, T. Erbengi, and O. N. Ulutin, The effect of defibrotide on thrombus formation in microarterial anostomosis. Internat. World Congr. of Neurological Surgery,Oct. 8–13 (1989), New Delhi.Google Scholar
  36. 36.
    C. Sala, E. Angelaccio, N. Lambardo, and G. Fumagalli, Morphometric and ultrastructural analysis of the antithrombotic activity of defibrotide. Cellular blood components in haemostasis and thrombosis, ed. by T. Barbui, S. Cartelazzo, P. Viero, S. Gorini and G. de Gaetano, John Libbey Eurotext, Paris, (1988) pp. 189–193.Google Scholar
  37. 37.
    A. Slier, S. Toplan, M. A. Ozdemir, O. N. ve Ulutin, Defibrotid’in taysanlarda DIC üzerine etkisi. (The effect of defibrotide on experimental DIC in rabbits). Hematoloji,IX:188–189, (1987).Google Scholar
  38. 38.
    C. Thiermann, P. Löbel, and K. Schrök, Uselfulness of defibrotide in protecting ischemic myocardium from early reperfusion damage. Amer. J. Cardiology, 56:978–982, (1985).CrossRefGoogle Scholar
  39. 39.
    M. S. Ugur: Defibrotide’ in trombosit ultrastrukturune etkisi. (The effect of defibrotide on platelet ultrastructure). Ph.D. thesis, Istanbul, (1986).Google Scholar
  40. 40.
    O. N. Ulutin, Clinical effectiveness of defibrotide in vasocclusive disorders and its mode of action. Seminars in Thrombosis and Haemostasis,14: Suppl. 1, 58–63, (1988).Google Scholar
  41. 41.
    O. N. Ulutin, Clinical effectiveness and mode action of defibrotide. Second Congr. Mediterranean Society of Therapy, July 20–25 (1986), Istanbul, p. 98.Google Scholar
  42. 42.
    O. N. Ulutin, The clinical and pharmacological results of defibrotide during treatment of POVD. 15th World Congress of Internat. Union of Angiology, Sept. 17–22, (1989), Rome.Google Scholar
  43. 43.
    O. N. Ulutin, S. Balkuv-Ulutin, G. Çizmeci, T. Ulutin, and B. Ferhanoglu, Some clinical pharmacological observations of the effect of defibrotide in human. Acta Pharmaceutica Turcica, 30:57–62, (1988).Google Scholar
  44. 44.
    O. N. Ulutin, S. Balkuv-Ulutin, M. S. Ugur, T. Ulutin, T. Erbengi, B. Ferhanoglu, and T. Yardimci, Defibrotide and its effects on platelet functions. 6th Meeting of the Danubian League Against Thrombosis and Haemorrhagic Disorders, May 31- June 3, (1989), Vienna, p. 48.Google Scholar
  45. 45.
    T. Ulutin, S. Balkuv-Ulutin, T. Yardimci, F. Demirkol, B. Ferhanoglu, and O. N. Ulutin, XXth National Congress of Haematology, Nov. 21–25, (1988) Ankara, Turkey p. 57.Google Scholar
  46. 46.
    O. N. Ulutin, G. Çizmeci, and S. Balkuv-Ulutin: Clinical pharmacology and mode of action of a new antithrombotic compound defibrotide. Folia Haematol., Leipzig, 115:177–180, (1988).Google Scholar
  47. 47.
    O.N. Ulutin, G. Çizmeci, and M. S. Ugur, Clinical pharmacology of defibrotide and its effect on platelet function (Abs. 189). Haemostasis, 18:, Suppl. 2, 143, (1988).Google Scholar
  48. 48.
    O. N. Ulutin, N. Ilhan-Berkel, and S. Belkuv-Ulutin, Some observations in man with a new extractive drug: defibrotide. Progress in Fibrinolysis VII, ed. by J. F. Davidson, M. B. Donati, S. Coccheri, Churcill-Livingstone, Edinburgh (1985), pp. 327–328.Google Scholar
  49. 49.
    O. N. Ulutin, N. Ilhan-Berkel, H. Tunali, M. Ozer, S. Balkuv-Ulutin, and Ç. Önsel, Effects of defibrotide on peripheral obliterative vascular diseases. Haemostasis, 16: Suppl. 1, 59–62, (1986).PubMedGoogle Scholar
  50. 50.
    O.N. Ulutin, and D. Sestakof, A study on hypercoagulability using heparin loading test. Henry Ford Hosp. Med. Bull. 8:63–67, (1960).Google Scholar
  51. 51.
    O. N. Ulutin, H. Tunali, G. Girisken, S. Aytis, M. S. Ugur, and S. Balkuv-Ulutin, The effect of fibrinolytic on electrically induced experimental venous thrombosis and vessel wall in dogs. XIIIth World Congr. of International Union of Angiology, Sept. 11–15, (1983) Rochester, Minnesota.Google Scholar
  52. 52.
    O. N. Ulutin, H. Tunali, G. Girisken, S. S. Aytis, M. S. Ugur, and S. Balkuv-Ulutin, The effect of fraction P, on the electrically induced thrombus formation in dogs. (7th Internat. Congr. on Thrombosis, Valencia, Oct. 1982) Haemostasis, 12:130, (1985).Google Scholar
  53. 53.
    O. N. Ulutin, H. Tunali, M. S. Ugur, S. Aytis, T. Erbengi, and S. Balkuv-Ulutin, Effect of defibrotide in electrically induced thrombosis in dogs. Haemostasis, 16: Suppl. 1, 9–12, (1986).PubMedGoogle Scholar
  54. 54.
    W. Weichert, H. K. Breddin, and J. Staubesand, Application of a laser-induced endothelial injury model in the screening of antithrombotic drugs. Seminars in Thrombosis and Hemostasis, 14:Suppl. 1, 108–114, (1988).Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • O. N. Ulutin
    • 1
  • S. Balkuv-Ulutin
    • 1
  • M. S. Ugur
    • 1
  • T. Ulutin
    • 1
  • Y. Özsoy
    • 1
  • G. Çizmeci
    • 1
  1. 1.Haemostasis and Thrombosis Research CenterCerrahpasa Medical School of Istanbul UniversityIstanbulTurkey

Personalised recommendations